Association between fatty liver index and controlled attenuation parameters as markers of metabolic dysfunction-associated fatty liver disease and bone mineral density: observational and two-sample Mendelian randomization studies

• Published in: Osteoporosis international 2024-04, Vol.35 (4), p.679-689
• Main Authors: Zeng, Lin, Li, Yan, Hong, Chang, Wang, Jiaren, Zhu, Hongbo, Li, Qimei, Cui, Hao, Ma, Pengcheng, Li, Ruining, He, Jingzhe, Zhu, Hong, Liu, Li, Xiao, Lushan
• Format: Article
• Language: English
• Subjects: Association analysis; Body mass index; Bone density; Bone mineral density; Comorbidity; Diabetes mellitus (non-insulin dependent); Endocrinology; Fatty liver; Femur; Genomes; Hyperlipidemia; Liver diseases; Magnetic resonance imaging; Medicine; Medicine & Public Health; Metabolism; Multivariate analysis; Original Article; Orthopedics; Osteopenia; Osteoporosis; Rheumatology; Single-nucleotide polymorphism; Steatosis
• ISSN: 0937-941X; 1433-2965
• DOI: 10.1007/s00198-023-06996-0

Summary Previously observational studies did not draw a clear conclusion on the association between fatty liver diseases and bone mineral density (BMD). Our large-scale studies revealed that MAFLD and hepatic steatosis had no causal effect on BMD, while some metabolic factors were correlated with BMD. The findings have important implications for the relationship between fatty liver diseases and BMD, and may help direct the clinical management of MAFLD patients who experience osteoporosis and osteopenia. Purpose Liver and bone are active endocrine organs with several metabolic functions. However, the link between metabolic dysfunction-associated fatty liver disease (MAFLD) and bone mineral density (BMD) is contradictory. Methods Using the UK Biobank and National Health and Nutrition Examination Survey (NHANES) dataset, we investigated the association between MAFLD, steatosis, and BMD in the observational analysis. We performed genome-wide association analysis to identify single-nucleotide polymorphisms associated with MAFLD. Large-scale two-sample Mendelian randomization (TSMR) analyses examined the potential causal relationship between MAFLD, hepatic steatosis, or major comorbid metabolic factors, and BMD. Results After adjusting for demographic factors and body mass index, logistic regression analysis demonstrated a significant association between MAFLD and reduced heel BMD. However, this association disappeared after adjusting for additional metabolic factors. MAFLD was not associated with total body, femur neck, and lumbar BMD in the NHANES dataset. Magnetic resonance imaging-measured steatosis did not show significant associations with reduced total body, femur neck, and lumbar BMD in multivariate analysis. TSMR analyses indicated that MAFLD and hepatic steatosis were not associated with BMD. Among all MAFLD-related comorbid factors, overweight and type 2 diabetes showed a causal relationship with increased BMD, while waist circumference and hyperlipidemia had the opposite effect. Conclusion No causal effect of MAFLD and hepatic steatosis on BMD was observed in this study, while some metabolic factors were correlated with BMD. This has important implications for understanding the relationship between fatty liver disease and BMD, which may help direct the clinical management of MAFLD patients with osteoporosis. Graphical Abstract